RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy

Abstract

Cellular metabolism is an intricate network satisfying bioenergetic and biosynthesis requirements of cells. Relevant studies have been constantly making inroads in our understanding of pathophysiology, and inspiring development of therapeutics. As a crucial component of epigenetics at post-transcription level, RNA modification significantly determines RNA fates, further affecting various biological processes and cellular phenotypes. To be noted, immunometabolism defines the metabolic alterations occur on immune cells in different stages and immunological contexts. In this review, we characterize the distribution features, modifying mechanisms and biological functions of 8 RNA modifications, including N6-methyladenosine (m6A), N6,2′-O-dimethyladenosine (m6Am), N1-methyladenosine (m1A), 5-methylcytosine (m5C), N4-acetylcytosine (ac4C), N7-methylguanosine (m7G), Pseudouridine (Ψ), adenosine-to-inosine (A-to-I) editing, which are relatively the most studied types. Then regulatory roles of these RNA modification on metabolism in diverse health and disease contexts are comprehensively described, categorized as glucose, lipid, amino acid, and mitochondrial metabolism. And we highlight the regulation of RNA modifications on immunometabolism, further influencing immune responses. Above all, we provide a thorough discussion about clinical implications of RNA modification in metabolism-targeted therapy and immunotherapy, progression of RNA modification-targeted agents, and its potential in RNA-targeted therapeutics. Eventually, we give legitimate perspectives for future researches in this field from methodological requirements, mechanistic insights, to therapeutic applications.

References 460

1. 1.
   MODOMICS: a database of RNA modification pathways. 2021 update · 2021

   No notice
2. 2.

   Yue Y, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 2015;29:1343-1355.

   Not in our library10.1101/gad.262766.115

3. 3.
   Metabolic landscape of the tumor microenvironment at single cell resolution · 2019

   No notice
4. 4.

   Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, adipose tissue and vascular dysfunction. Circ. Res. 2021;128:951-968.

   Not in our library10.1161/circresaha.121.318093

5. 5.

   Boulton A. Strengthening the International Diabetes Federation (IDF). Diabetes Res Clin. Pract. 2020;160:108029.

   Not in our library10.1016/j.diabres.2020.108029

6. 6.

   Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212-2224.

   Not in our library10.1016/s0140-6736(20)32511-3

7. 7.

   Long GV, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20:1083-1097.

   Not in our library10.1016/s1470-2045(19)30274-8

8. 8.

   Tannir NM, et al. Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial. JAMA Oncol. 2022;8:1411-1418.

   Not in our library10.1001/jamaoncol.2022.3511

9. 9.

   Goodwin PJ, et al. Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA. 2022;327:1963-1973.

   Not in our library10.1001/jama.2022.6147

10. 10.
    The role of m6A RNA methylation in cancer metabolism · 2022

    No notice
11. 11.

    Cai X, et al. N6-methyladenosine modification and metabolic reprogramming of digestive system malignancies. Cancer Lett. 2022;544:215815.

    Not in our library10.1016/j.canlet.2022.215815

12. 12.
    m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism · 2023

    No notice
13. 13.

    Everts B, et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood. 2012;120:1422-1431.

    Not in our library10.1182/blood-2012-03-419747

14. 14.

    Akkaya M, et al. Second signals rescue B cells from activation-induced mitochondrial dysfunction and death. Nat. Immunol. 2018;19:871.

    Not in our library10.1038/s41590-018-0156-5

15. 15.

    Lauterbach MA, et al. Toll-like receptor signaling rewires macrophage metabolism and promotes histone acetylation via ATP-citrate lyase. Immunity. 2019;51:997.

    Not in our library10.1016/j.immuni.2019.11.009

16. 16.

    Wang RN, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011;35:871-882.

    Not in our library10.1016/j.immuni.2011.09.021

17. 17.

    Cohn WE, Volkin E. Nucleoside-5′-phosphates from ribonucleic acid. Nature. 1951;167:483-484.

    Not in our library10.1038/167483a0

18. 18.

    Holley RW, Everett GA, Madison JT, Zamir A. Nucleotide sequences in the yeast alanine transfer ribonucleic acid. J. Biol. Chem. 1965;240:2122-2128.

    Not in our library10.1016/s0021-9258(18)97435-1

19. 19.

    Jia GF, et al. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 2011;7:885-887.

    Not in our library10.1038/nchembio.687

20. 20.

    Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc. Natl Acad. Sci. USA. 1974;71:3971-3975.

    Not in our library10.1073/pnas.71.10.3971

21. 21.

    Adams JM, Cory S. Modified nucleosides and bizarre 5′-termini in mouse myeloma mRNA. Nature. 1975;255:28-33.

    Not in our library10.1038/255028a0

22. 22.
    Modifications and functional genomics of human transfer RNA · 2018

    No notice
23. 23.

    Lyons SM, Fay MM, Ivanov P. The role of RNA modifications in the regulation of tRNA cleavage. FEBS Lett. 2018;592:2828-2844.

    Not in our library10.1002/1873-3468.13205

24. 24.

    Jacob R, Zander S, Gutschner T. The dark side of the epitranscriptome: chemical modifications in long non-coding RNAs. Int J. Mol. Sci. 2017;18:2387.

    Not in our library10.3390/ijms18112387

25. 25.
    Aberrant NSUN2-mediated m5C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma · 2020

    No notice
26. 26.

    Meyer KD, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149:1635-1646.

    Not in our library10.1016/j.cell.2012.05.003

27. 27.

    Huang H, Weng H, Chen J. m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37:270-288.

    Not in our library10.1016/j.ccell.2020.02.004

28. 28.

    Wang Y, et al. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat. Cell Biol. 2014;16:191-198.

    Not in our library10.1038/ncb2902

29. 29.

    Fustin JM, et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. Cell. 2013;155:793-806.

    Not in our library10.1016/j.cell.2013.10.026

30. 30.

    Aguilo F, et al. Coordination of m(6)A mRNA methylation and gene transcription by ZFP217 regulates pluripotency and reprogramming. Cell Stem Cell. 2015;17:689-704.

    Not in our library10.1016/j.stem.2015.09.005

31. 31.

    Schwartz S, et al. High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis. Cell. 2013;155:1409-1421.

    Not in our library10.1016/j.cell.2013.10.047

32. 32.
    FTO is required for myogenesis by positively regulating mTOR-PGC-1α pathway-mediated mitochondria biogenesis · 2017

    No notice
33. 33.

    Dina C, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat. Genet. 2007;39:724-726.

    Not in our library10.1038/ng2048

34. 34.

    Liu J, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 2014;10:93-95.

    Not in our library10.1038/nchembio.1432

35. 35.

    Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol. Cell. 2016;63:306-317.

    Not in our library10.1016/j.molcel.2016.05.041

36. 36.
    Solution structure of the RNA recognition domain of METTL3-METTL14 N6-methyladenosine methyltransferase · 2018

    No notice
37. 37.

    Ping XL, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177-189.

    Not in our library10.1038/cr.2014.3

38. 38.

    Patil DP, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537:369-373.

    Not in our library10.1038/nature19342

39. 39.

    Bokar JA, et al. Characterization and partial purification of mRNA N6-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. J. Biol. Chem. 1994;269:17697-17704.

    Not in our library10.1016/s0021-9258(17)32497-3

40. 40.

    Pendleton KE, et al. The U6 snRNA m(6)A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 2017;169:824.

    Not in our library10.1016/j.cell.2017.05.003

Cited by papers we hold 1

• Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance · 2025
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.